The prevalence of its use for depressive disorders ranges between 18% and 26% and for anxiety disorders between 6% and 26 % Medina-Mora et al., 1997; Medina-Mora et al., 2003; Berenzon et al., 2009.
Las prevalencias de uso para trastornos depresivos oscila entre el 18% y el 26% y para trastornos de ansiedad de 8% a 26% Medina-Mora et al., 1997; Medina-Mora et al., 2003; Berenzon et al., 2009.